American Herbal Products Association (AHPA) > News

AHPA submits comments to DEA

The American Herbal Products Association (AHPA) expressed strong support for the Drug Enforcement Agency (DEA) using its temporary scheduling authority to place synthetic cannabinoids into schedule I in comments submitted to the agency.

AHPA responds to inaccurate media coverage of curcumin mini-perspective

Mini-perspective has been misinterpreted to create inaccurate headlines and articles that misinform the public about turmeric

AHPA Chief Science Officer Maged Sharaf, Ph.D., responded to inaccurate media coverage of a mini-perspecive, "The Essential Medicinal Chemistry of Curcumin,"

Sharaf to discuss AHPA initiatives at 17th annual ICBS in Mississippi

IADSA update on international supplement regulations

IADSA December 2016 Newsflash

This issue of the IADSA Newsflash includes an update on the Association of Southeast Asian Nations (ASEAN) Agreement on Regulatory Framework for Health Supplements deadline for implementation, which will be pushed back to March 2023.

FSMA Direct Impacts to Most AHPA Members

Regulatory experts provide a road map to FSMA understanding requirements and compliance

Webinar recorded Dec. 15, 2016. Member cost: $199. Nonmember cost: $499.

FDA Inspections, Warning Letters and Emerging cGMP Compliance Issues

Learn the elements of 21 CFR 111 / current Good Manufacturing Practice (cGMP) regulations that FDA inspections have been focusing on recently

Webinar recorded Dec. 13, 2016. Member cost: $199. Nonmember cost: $499.

AHPA submits comments to FDA on revised NDI draft guidance

Draft NDI guidance fails to achieve FDA's stated goals and is contrary to intent of the law

In comments submitted to the Food and Drug Administration (FDA), the American Herbal Products Association (AHPA) expressed concern that the latest revision of draft guidance for New Dietary Ingredients (NDIs) is unlikely to achieve FDA's stated goals and is contrary to the intent of the law in numerous areas.

AHPA submits comments to DEA on potential impacts of scheduling herbal constituents

DEA should avoid restricting research on new medical uses, health benefits, or other uses for botanicals

In comments submitted last week to the Drug Enforcement Agency (DEA), the American Herbal Products Association (AHPA) urged the agency to refrain from using its authority to effectively remove a plant from the existing marketplace because naturally occurring constituents become scheduled under the Controlled Substances Act (CSA).

AHPA Updates

Subscribe >>